THINKING BEYOND GLP‑1 with formoline L112 EXTRA.
THINKING BEYOND GLP‑1 with formoline L112 EXTRA.
Rapid success with GLP‑1 – but what comes next?
As GLP‑1 alone does not constitute holistic weight management,1,2 formoline® L112 EXTRA can provide support: as pre‑ or post‑therapy to GLP‑1 and as a complement to guideline‑based basic therapy.2
formoline L112 EXTRA
formoline L112 EXTRA is a lipid binder based on polyglucosamine L112. It binds dietary fats and reduces fat absorption.
Weight reduction
Significant and clinically relevant weight reduction: 50% more effective than basic therapy³
Good adherence
Simple administration: two tablets twice daily, taken with the main meals with the highest fat content4
Very good tolerability
Compared with therapies such as orlistat, formoline L112 EXTRA is very well tolerated and easy to use4
Costs
Monthly costs of approximately €77 – significantly lower than GLP‑1 agonists5
THINKING BEYOND GLP‑1:
Weight management models
formoline L112 EXTRA can support patients depending on their individual baseline situation — either after weight reduction with GLP‑1 or before and after GLP‑1‑supported weight loss.
formoline Model 1:
POST–GLP-1
Model 1 is relevant for a wide range of patients who meet the following criteria:
- Desire to limit the duration of GLP‑1 treatment
- Occurrence of side effects that are no longer tolerable
- Patient must consider costs
- Awareness of a documented yo‑yo effect¹
Maintaining the achieved weight
formoline Model 2:
PRE‑ and POST‑GLP‑1
Model 2 is relevant for patients who meet the following criteria:
- Patients are sensitive with regard to costs, side effects or fear of injections and are still undecided
- Initial therapy with formoline L112 EXTRA plus basic therapy
- Option to further increase weight reduction through a time‑limited use of GLP‑1
- Weight stabilisation
formoline Model 1:
POST–GLP-1
Model 1 is relevant for a wide range of patients who meet the following criteria:
- Desire to limit the duration of GLP‑1 treatment
- Occurrence of side effects that are no longer tolerable
- Patient must consider costs
- Awareness of a documented yo‑yo effect¹
Maintaining the achieved weight
formoline Model 2:
PRE‑ and POST‑GLP‑1
Model 2 is relevant for patients who meet the following criteria:
- Patients are sensitive with regard to costs, side effects or fear of injections and are still undecided
- Initial therapy with formoline L112 EXTRA plus basic therapy
- Option to further increase weight reduction through a time‑limited use of GLP‑1
- Weight stabilisation
Study results
on weight reduction with formoline L112
Results of a double‑blind, randomised study with 100 participants with a BMI > 30 to ≤ 35 after one year of therapy with the lower‑dose preparation formoline L112 in combination with lifestyle modification showed the following outcomes:³
Ergebnisse einer doppelblinden, randomisierten Studie mit 100 Teilnehmerinnen und Teilnehmern mit einem BMI > 30 bis ≤ 35 zeigten nach einem Jahr Therapie mit dem niedriger dosierten Präparat formoline L112 in Kombination zu einer Lebensstilveränderung folgende Ergebnisse:3
formoline L112:
WEIGHT LOSS OF
12.1 KG
REDUCTION IN WAIST CIRCUMFERENCE OF
13,3 CM
Placebo
WEIGHT LOSS OF
8.0 KG
REDUCTION IN WAIST CIRCUMFERENCE
10 CM
Lifestyle modification
Lifestyle modification consisted of a 10% reduction in caloric intake and an increase in physical activity of 9 metabolic equivalent hours per week.³
Slow walking
One hour of slow walking corresponds to 2 metabolic equivalent hours.³
Brisk walking
One hour of brisk walking corresponds to 3.3 metabolic equivalent hours.³
Change in body weight with formoline L112 compared to placebo³
Significantly greater weight reduction with PG L112 compared with placebo (≥ 50 % greater weight loss after 12 months)³
MODE OF ACTION
The main active component of formoline L112 EXTRA is polyglucosamine L112.
The functional fibre polyglucosamine L112 effectively binds dietary fats and cholesterol in the gastrointestinal tract through a combination of hydrophobic and electrostatic interactions. In the acidic environment of the stomach, polyglucosamine becomes protonated at its free amino groups, resulting in positively charged amino groups (‑NH₃⁺). The long‑chain fatty acids of lipids interact with the polysaccharide structure and the remaining acetyl groups, while free fatty acids are predominantly bound via ionic bonds between the negatively charged carboxyl groups of the fatty acids (‑COO⁻) and the positive charges of polyglucosamine L112. This acts as a polar anchor group for hydrophobic interactions. A gel structure is formed which, due to its lipophilic character, can bind additional lipophilic substances such as cholesterol and neutral fats.
Absorption
By binding lipids to polyglucosamine L112, the absorption of lipids through the intestinal wall is significantly reduced. In animal studies, a reduction in lipid absorption of up to 66% was demonstrated.6
Optimal effect
When formoline L112 EXTRA is taken according to the dosing recommendation with a fat‑containing meal, the polyglucosamine gel that forms can have its optimal effect.4
FAQ
Thinking beyond GLP‑1
formoline L112 EXTRA acts purely physically and locally in the gastrointestinal tract and is not absorbed into the body.4
Results of a double‑blind, randomised study involving 100 participants with a BMI > 30 to ≤ 35 showed a weight loss of 12.1 kg after one year of therapy with the lower‑dose preparation formoline L112 in combination with lifestyle modification.3
Within one year, waist circumference can be reduced by 13.3 cm. This is a good indicator of a reduction in visceral abdominal fat.3 This has a positive effect on metabolic syndrome.
Practice UpdateS
Stay Informed